Bernard P, Bedane C, Bonnetblanc JM Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol. 1997 May;136(5):694-8.
Cooper HL, Healy E, Theaker JM, Friedmann PS Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol. 2003 Jul;28(4):366-8.
Gault MH, Purchase L Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? CMAJ. 1992 Sep 15;147(6):845-7.
Giudice GJ, Liu Z, Diaz LA An animal model of bullous pemphigoid: what can it teach us? Proc Assoc Am Physicians. 1995 Jul;107(2):237-41. Review.
Goebeler M, Herzog S, Bröcker EB, Zillikens D Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003 Oct;149(4):899-901.
Herrmann G, Hunzelmann N, Engert A Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003 Mar;148(3):602-3.
Korman NJ Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy. Arch Dermatol. 1998 Sep;134(9):1137-41. Review.
Leandro MJ, Edwards JC, Cambridge G Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002 Oct;61(10):883-8.
Salopek TG, Logsetty S, Tredget EE Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002 Nov;47(5):785-8.
Stasi R, Pagano A, Stipa E, Amadori S Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001 Aug 15;98(4):952-7.
Stasi R, Stipa E, Forte V, Meo P, Amadori S Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002 May 15;99(10):3872-3.
Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 2002 Sep;30(5):327-9.
Venning VA, Wojnarowska F Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992 Apr;26(4):585-9.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
